<DOC>
	<DOCNO>NCT02231580</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics pharmacodynamics BN82451B versus placebo oral administration twice daily ( bid ) 28 day patient Huntington 's Disease ( HD ) .</brief_summary>
	<brief_title>Study Exploring Safety , Pharmacokinetic Pharmacodynamic BN82451 Male Huntington 's Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Huntington Disease</mesh_term>
	<criteria>Male subject 20 70 year old ( inclusive ) . Provision write informed consent prior study related procedure . In study consent may provide legal guardian carer . Confirmed symptomatic Huntington 's Disease diagnose base clinical feature ( i.e . Diagnostic Confidence Level equal 4 ) presence least 36 cytosine adenine guanine ( CAG ) repeat Huntington gene document copy previous genetic test report . Unified Huntington 's Disease Rated ScaleTotal Motor Score ( UDHRSTMS ) great equal 15 . Ambulatory . UDHRSTotal Functional Capacity ( TFC ) great equal 3 ( i.e . Shoulson &amp; Fahn Scale stag 13 inclusive . Subjects antipsychotic , antidepressant , anxiolytic hypnotic therapy must stable treatment 4 week prior study drug start study period . Able swallow study medication . Able perform QMotor test . If partner risk pregnancy , subject agrees use condom abstinent 14 day last intake study drug . Juvenile form Huntington 's Disease . Any form chorea Huntington 's Disease . History seizure , epilepsy convulsive disorder , exception febrile seizures childhood . History condition susceptible induce seizure severe traumatic brain injury , brain tumour , stroke . History neurosurgical procedure . Current evidence history ( within 1 year Baseline ) psychosis , hallucination delusion , include major depression psychotic feature , define Diagnostic Statistical Manual , Fourth Edition , Text Revision ( DSMIVTR ) . Patients currently experience mild depression , moderate depression adequately appropriately treated judgement investigator , participate depression expect interfere study participation . History drug and/or alcohol abuse per DSM IVTR criterion within 12 month prior Baseline . At imminent risk self harm base investigator 's clinical judgment , `` yes '' answer item 4 5 ColumbiaSuicide Severity Rating Scale ( CSSRS ) questionnaire . Mini Mental State Exam ( MMSE ) total score less equal 23 . Used investigational drug within 30 day prior Screening 5 half life , whichever long . Known allergy/sensitivity study drug excipients . A severe ongoing unstable medical condition ( e.g . cardiac , hepatic , renal , metabolic endocrine ) . Any clinically significant condition , opinion investigator , would interfere trial evaluation optimal participation trial . Any significant laboratory result , investigator 's opinion , would compatible study participation represent risk subject study . History malignant disease within 5 year prior Screening ( exception basal cell squamous cell carcinoma skin completely excise , situ prostate cancer normal prostate specific antigen ) . An estimated Creatinine Clearance ( CrCl ) less 60 mL/minute ( use CockcroftGault formula ) . Alanine Aminotransferase ( ALT ) /Aspartate Aminotransferase ( AST ) value great equal 2 time Upper Limit Normal range ( ULN ) GGT ALT value great three time ULN . Known history hepatitis B C Human Immunodeficiency Virus ( HIV ) positive serology Screening . Corrected QT interval use Bazett 's correction ( QTcB ) great 450 m clinically significant ECG finding . Receiving tetrabenazine within 4 week prior Baseline . Taking follow prohibited medications/substances : Strong Cytochrome ( CYP ) 3A4 inhibitor Strong CYP3A4 inducer ( Wash prior Baseline 30 day 5 half life , whichever long ) , CYP2B6 substrates , CYP1A2 substrates , CYP3A4 substrates , CYP2C19 substrates ( assessed case case basis )</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Neurodegenerative genetic disorder</keyword>
</DOC>